Literature DB >> 25973337

Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.

Saima Muzahir1, Robert Jeraj2, Glenn Liu3, Lance T Hall1, Alejandro Munoz Del Rio1, Timothy Perk2, Christine Jaskowiak1, Scott B Perlman1.   

Abstract

Fluorine 18 Sodium Fluoride ((18)F-NaF) (sodium fluoride) PET/CT is a highly sensitive but is a non-specific method for identifying bone metastases. Qualitative scan interpretation using low dose CT for lesion localization is often complicated by the presence of co-existing degenerative joint disease (DJD). A semi-quantitative analysis might help in accurately differentiating benign from metastatic osseous lesions. The aim of the study was to evaluate the clinical utility of (18)F-NaF PET/CT in differentiating DJD from metastatic disease in the skeleton using a qualitative analysis as well as a semi-quantitative approach using the SUVmax and to determine if there is an upper limit of SUVmax value that can reliably differentiate metastases from DJD. Baseline (18)F-NaF PET/CT scans were performed for 17 castrate resistant prostate cancer patients (CRPC). A qualitative as well as semi-quantitative analysis using maximum standardized uptake value (SUVmax) based on body weight was performed for 65 metastatic and 56 DJD sites identified on the low dose CT scan acquired as a part of whole body PET/CT scan. The SUVmax range in DJD was 2.6-49.9 (mean: 6.2). The SUVmax range for metastatic lesions was 11.2-188 (mean: 160). The SUVmax value for metastatic as well as areas of DJD showed significant variation during treatment. Bone metastases showed statistically significantly higher SUVmax than DJD using a mixed effect regression model. ROC/AUC analysis was performed based on averaging the SUVs over all lesions in each subject. The AUC was found to be fairly high at 0.964 (95% CI: 0.75-0.996). The SUVmax over 50 always represented a bone metastasis and below 12 always represented a site of DJD. The results of our preliminary data show that semi-quantitative analysis is complementary to the qualitative analysis in accurately identifying DJD from metastatic disease. The cut-off SUVmax of 50 can help in differentiating DJD from bone metastases.

Entities:  

Keywords:  F-18 NaF; PET/CT; bone metastases; castrate resistant prostate cancer; degenerative joint disease

Year:  2015        PMID: 25973337      PMCID: PMC4396008     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  28 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

Review 2.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.

Authors:  G M Blake; S J Park-Holohan; G J Cook; I Fogelman
Journal:  Semin Nucl Med       Date:  2001-01       Impact factor: 4.446

3.  Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT.

Authors:  Ron S Rosen; Laura Fayad; Richard L Wahl
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

4.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; H Ishijima; N Oya; N Sato; T Inoue; K Endo
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

Review 5.  Radiological imaging for the diagnosis of bone metastases.

Authors:  L D Rybak; D I Rosenthal
Journal:  Q J Nucl Med       Date:  2001-03

6.  Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET.

Authors:  R A Hawkins; Y Choi; S C Huang; C K Hoh; M Dahlbom; C Schiepers; N Satyamurthy; J R Barrio; M E Phelps
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

Review 7.  The role of positron emission tomography in the management of bone metastases.

Authors:  G J Cook; I Fogelman
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

8.  Precision of ¹⁸F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism.

Authors:  Y Al-Beyatti; M Siddique; M L Frost; I Fogelman; G M Blake
Journal:  Osteoporos Int       Date:  2012-01-12       Impact factor: 4.507

9.  Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.

Authors:  C Schiepers; J Nuyts; G Bormans; J Dequeker; R Bouillon; L Mortelmans; A Verbruggen; M De Roo
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

Review 10.  Bone imaging in metastatic breast cancer.

Authors:  Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

View more
  10 in total

Review 1.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

2.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

3.  Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.

Authors:  Stephanie A Harmon; Timothy Perk; Christie Lin; Jens Eickhoff; Peter L Choyke; William L Dahut; Andrea B Apolo; John L Humm; Steven M Larson; Michael J Morris; Glenn Liu; Robert Jeraj
Journal:  J Clin Oncol       Date:  2017-06-27       Impact factor: 44.544

4.  Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion.

Authors:  Jeong Won Lee; Yong-Jin Park; Youn Soo Jeon; Ki Hong Kim; Jong Eun Lee; Sung Hoon Hong; Sang Mi Lee; Su Jin Jang
Journal:  Quant Imaging Med Surg       Date:  2020-11

5.  Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Authors:  Christie Lin; Tyler Bradshaw; Timothy Perk; Stephanie Harmon; Jens Eickhoff; Ngoneh Jallow; Peter L Choyke; William L Dahut; Steven Larson; John Laurence Humm; Scott Perlman; Andrea B Apolo; Michael J Morris; Glenn Liu; Robert Jeraj
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

6.  A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.

Authors:  Ulka N Vaishampayan; Omid S Tehrani; Jawana M Lawhorn-Crews; Lance K Heilbrun; Kimberlee Dobson; Daryn Smith; Brenda Dickow; Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 7.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

Review 8.  Contemporary approaches for imaging skeletal metastasis.

Authors:  David Ulmert; Lilja Solnes; Daniel Lj Thorek
Journal:  Bone Res       Date:  2015-07-14       Impact factor: 13.567

9.  Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.

Authors:  Ichiei Kuji; Tomohiko Yamane; Akira Seto; Yota Yasumizu; Suguru Shirotake; Masafumi Oyama
Journal:  Eur J Hybrid Imaging       Date:  2017-10-12

10.  68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases.

Authors:  Rui Guo; Xiangxi Meng; Fei Wang; Jiangyuan Yu; Qing Xie; Wei Zhao; Lin Zhu; Hank F Kung; Zhi Yang; Nan Li
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.